Haemonetics CORP Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NYSE
Martin D Madaus, a Director of Haemonetics Corp, received 2,538 shares of common stock on July 24, 2026.
NYSE
Ellen M Zane, a Director of Haemonetics Corp, received 2,538 shares of common stock on July 24, 2026.
NYSE
Claire Pomeroy, a Director of Haemonetics Corp, received 2,538 shares of common stock on July 24, 2026.
NYSE
Mark W Kroll, a Director of Haemonetics Corp, received 2,538 shares of common stock on July 24, 2026.
NYSE
Lloyd Emerson Johnson, a Director of Haemonetics Corp, received 2,538 shares of common stock on July 24, 2026.
NYSE
Michael J Coyle, a Director of Haemonetics Corp, received 2,538 shares of common stock on July 24, 2026.
NYSE
Diane M Bryant, a Director of Haemonetics Corp, received 2,538 shares of common stock on July 24, 2026.
NYSE
Robert E Abernathy, a Director of Haemonetics Corp, received 2,538 shares of common stock on July 24, 2026.
NYSE
Haemonetics Corp reports a transaction where VP, Chief Accounting Officer Maryanne Farris sold shares to cover tax obligations related to vested RSUs.
NYSE
Laurie A. Miller, SVP of Human Resources at Haemonetics Corp, reported a transaction involving common stock on June 5, 2026.
NYSE
Haemonetics Corporation EVP and General Counsel Michelle L. Basil reported the vesting of restricted stock units and associated tax withholding.
NYSE
Haemonetics Corporation EVP and COO Frank Chan reported the vesting of restricted stock units and the withholding of shares for tax obligations.
NYSE
Haemonetics Corporation EVP and CFO James D'Arecca reported the vesting of restricted stock units and associated tax withholding.
NYSE
Haemonetics Corporation Chief Accounting Officer Maryanne Maunsell Farris reported the vesting of restricted stock units and a new equity grant.
NYSE
EVP and Chief Commercial Officer Roy Galvin reported the vesting of restricted stock units and subsequent tax withholding in a recent SEC Form 4 filing.
NYSE
Haemonetics Corporation SVP of Human Resources Laurie A. Miller reported the vesting of restricted stock units and associated tax withholding.
NYSE
Haemonetics Corporation reports changes in beneficial ownership for President & CEO Christopher Simon, including stock transactions and RSU vesting.
NYSE
Haemonetics Corp. EVP and Chief Financial Officer James D'Arecca reported a transaction involving the withholding of shares for tax obligations related to vested RSUs.
NYSE
Haemonetics Director Mark W. Kroll purchased 1,400 shares of common stock at $70.56 per share.
NYSE
Haemonetics EVP, Chief Commercial Officer Roy Galvin reported a transaction involving shares withheld for tax obligations related to RSU vesting.
NYSE
Haemonetics' SVP of Human Resources, Laurie A. Miller, disposed of 238 shares of common stock to cover tax obligations related to restricted stock unit vesting.
NYSE
Haemonetics Corporation Director Ellen M. Zane was granted 2,693 restricted stock units, increasing her beneficial ownership to 19,373 shares.
NYSE
Haemonetics Corporation's Director, Claire Pomeroy, was granted 2,693 restricted stock units as part of the company's long-term incentive plan.
NYSE
Haemonetics Corporation Director Mark W. Kroll was awarded 2,693 restricted stock units as part of the company's long-term incentive compensation plan.
NYSE
Haemonetics Corporation Director Lloyd Emerson Johnson was granted 2,693 restricted stock units as part of the company's long-term incentive plan.
NYSE
Haemonetics Corp. Director Charles J. Dockendorff acquired 2,693 restricted stock units as part of the company's long-term incentive plan.
NYSE
Haemonetics Corporation's Director, Michael J. Coyle, was granted 2,693 restricted stock units, aligning his interests with shareholders.
NYSE
Haemonetics Corporation's Director, Diane M. Bryant, was granted 2,693 restricted stock units (RSUs) as part of the company's long-term incentive plan.
NYSE
Haemonetics Corporation's Director, Robert E. Abernathy, was granted 2,693 restricted stock units as part of the company's long-term incentive plan.
NYSE
Haemonetics Corp's EVP and General Counsel, Michelle L. Basil, filed an amended SEC Form 4 to correct previously reported restricted stock unit and stock option awards.